Oppenheimer Upgrades Blueprint Medicines to Outperform, Announces $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has upgraded Blueprint Medicines (NASDAQ:BPMC) from Perform to Outperform and set a new price target of $85.
October 27, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines has been upgraded to Outperform by Oppenheimer, with a new price target of $85.
The upgrade from Oppenheimer is a positive signal for Blueprint Medicines. The new price target of $85 suggests that the analyst sees significant upside potential for the stock. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100